Highlights Newsletter 1
This newsletter presents you the following key sessions:
- Watch the video interview with professor E. Van Cutsem about the initial results of the phase III LUME-colon 1 study with nintedanib versus best supportive care
- Niraparib significantly delays disease progression in patients with platinum-sensitive ovarian cancer
- Fulvestrant delays disease progression in women with endocrine-therapy naïve advanced hormone-receptor positive breast cancer
- Significant survival benefit with atezolizumab over docetaxel in patients with previously treated non-small cell lung cancer
- Confirmed durable efficacy of dabrafenib plus trametinib as first-line treatment for advanced BRAF-mutant cutaneous melanoma
